Elevated asymmetric dimethylarginine in plasma: An early marker for endothelial dysfunction in non-alcoholic fatty liver disease?

Diabetes Research and Clinical Practice

Volumn 96, Issue 1, 2012, Pages 47-52

  Dogru, Teoman ^a   Genc, Halil ^a   Tapan, Serkan ^a   Ercin, Cemal Nuri ^a   Ors, Fatih ^a   Aslan, Fatih ^a   Kara, Muammer ^a   Sertoglu, Erdim ^a   Bagci, Sait ^a   Kurt, Ismail ^a   Sonmez, Alper ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Asymmetric dimethylarginine; Carotid artery intima media thickness; Nonalcoholic fatty liver disease

Indexed keywords

GLUCOSE; INSULIN; LIPID; N(G),N(G) DIMETHYLARGININE;

ADULT; AMINO ACID BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERIOGRAPHY; CAROTID ATHEROSCLEROSIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; RISK ASSESSMENT;

ADULT; ARGININE; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; FATTY LIVER; HUMANS; MALE; YOUNG ADULT;

EID: 84858748832     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.11.022     Document Type: Article

References (35)

1. Kim C.H., Younossi Z.M. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008, 75:721-728.
2. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010, 11:430-445.
3. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
4. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008, 49:600-617.
5. Yesilova Z., Yaman H., Oktenli C., Ozcan A., Uygun A., Cakir E., et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:850-855.
6. Targher G., Bertolini L., Scala L., Zoppini G., Zenari L., Falezza G. Nonalcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in nondiabetic men. Role of visceral adipose tissue. Diabet Med 2005, 22:1354-1358.
7. Polyzos S.A., Kountouras J., Zavos C., Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010, 12:365-383.
8. Sozio M.S., Liangpunsakul S., Crabb D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin Liver Dis 2010, 30:378-390.
9. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
10. Siervo M., Corander M., Stranges S., Bluck L. Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA). Nutr Metab Cardiovasc Dis 2011, 21:1-10.
11. Böger R.H., Maas R., Schulze F., Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-An update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009, 60:481-487.
12. Villanova N., Moscatiello S., Ramilli S., Bugianesi E., Magalotti D., Vanni E. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42:473-480.
13. Senturk O., Kocaman O., Hulagu S., Sahin T., Aygun C., Konduk T., et al. Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. Intern Med J 2008, 38:183-189.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.
17. Diagnosis and classification of diabetes mellitus. ADA position statements. Diabetes Care 2011, 34:62-69.
18. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
19. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-229.
20. Simon A., Megnien J.L., Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler Thromb Vasc Biol 2010, 30:182-185.
21. Petit J.M., Guiu B., Terriat B., Loffroy R., Robin I., Petit V., et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 2009, 94:4103-4106.
22. McKimmie R.L., Daniel K.R., Carr J.J., Bowden D.W., Freedman B.I., Register T.C., et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study. Am J Gastroenterol 2008, 103:3029-3035.
23. Fracanzani A.L., Burdick L., Raselli S., Pedotti P., Grigore L., Santorelli G., et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008, 121:72-78.
24. Targher G., Bertolini L., Padovani R. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29:1325-1330.
25. Matsumoto K., Sera Y., Abe Y., Tominaga T., Yeki Y., Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004, 64:225-228.
26. Crouse J.R., Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O'Leary D.H., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007, 297:1344-1353.
27. Wang J.G., Staessen J.A., Li Y., Van Bortel L.M., Nawrot T., Fagard R., et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006, 37:1933-1940.
28. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
29. Chen W., Srinivasan S.R., Li S., Xu J., Berenson G.S. Metabolic syndrome variables at low levels in childhood are beneficially associated with adulthood cardiovascular risk: the Bogalusa Heart Study. Diabetes Care 2005, 28:126-131.
30. Manco M., Bedogni G., Monti L., Morino G., Natali G., Nobili V. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis 2010, 209:463-468.
31. Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009, 204:521-525.
32. Zsuga J., Török J., Magyar M.T., Valikovics A., Gesztelyi R., Lenkei A., et al. Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. Metabolism 2007, 56:394-399.
33. Can A., Bekpinar S., Gurdol F., Tutuncu Y., Unlucerci Y., Dinccag N. Dimethylarginines in patients with type 2 diabetes mellitus: relation with the glycaemic control. Diabetes Res Clin Pract 2011 September 1, [Epub ahead of print].
34. Krzyzanowska K., Mittermayer F., Wolzt M., Schernthaner G. ADMA, cardiovascular disease and diabetes. Diabetes Res Clin Pract 2008, 82:122-126.
35. Kasumov T., Edmison J.M., Dasarathy S., Bennett C., Lopez R., Kalhan S.C. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism 2011, 60:776-781.